Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
JNJ-303 is an inhibitor of voltage-gated potassium channel Kv7.1 (IC50 = 0.064 µM).1 It is selective for inhibiting Kv7.1 currents (IKs) over INa, IKr, Ito, IK1, and ICaL (IC50s =3.3, 12.6, 11.1, >100, and >10 µM, respectively). It selectively inhibits the heteromeric Kv7.1-KCNE1 complex (IC50 = 0.0784 µM) with no effect on homomeric Kv7.1, Kv7.2, or Kv1.5 in Xenopus oocytes at 1 µM.2 JNJ-303 prolongs the QT interval and also induces pause-dependent torsade de pointes (TdP) in anesthetized dogs when used at doses of 0.63 and 1.25 mg/kg, respectively.1
WARNING This product is not for human or veterinary use.
1. Blockade of the IKS potassium channel: An overlooked cardiovascular liability in drug safety screening? J. Pharmacol. Toxicol. Methods 60(1), 1-10 (2009).
2. KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting. Nat. Commun. 7, 12795 (2016).